Prescribing information (external link)
LEQVIO® (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:1
in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1
For full safety information, please refer to the LEQVIO® Summary of Product Characteristics (SmPC).
LEQVIO® (inclisiran) in secondary care
Getting started with LEQVIO® in secondary care
Watch the video below to learn how LEQVIO® can be integrated into established clinical pathways in secondary care settings.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1
For full safety information, please refer to the LEQVIO® SmPC.
Prescribing information (external link)
Making LEQVIO® routine in secondary care
Watch the video below to learn how LEQVIO® could be used routinely in eligible patients within a secondary care setting.
The effect of LEQVIO® on cardiovascular morbidity and mortality has not yet been determined.1
For full safety information, please refer to the LEQVIO® SmPC.
Prescribing information (external link)
Please get in touch with us to speak to one of our Novartis representatives
SmPC, summary of product characteristics.
Reference
LEQVIO® Summary of Product Characteristics.
UK | June 2026 | FA-11695603
